Brief: Acadia Pharmaceuticals Q4 EPS USD 0.86 Vs. IBES Estimate USD 0.22
26/02/2025 21:05
Feb 26 (Reuters) - Acadia Pharmaceuticals Q4 net income USD 143.742 million vs. IBES estimate USD 40.8 million. Q4 operating expenses USD 106.099 million Q4 pretax profit USD 161.085 million vs. IBES estimate USD 45.3 million Q4 product sales USD 259.602 million vs. IBES estimate USD 277.7 million
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP